Markets are being pulled in many directions right now, from energy shocks and stubborn inflation to shifting central bank policies and uneven growth signals across the US, Europe and Asia. When so many moving parts affect rates, currencies and input costs, it can help to anchor a portfolio in companies that our model scores as lower risk with resilient balance sheets. This Low-Risk Leaders screener focuses on stocks with the smallest risk scores in the tool, with the goal of reducing portfolio swings without sacrificing potential returns. Below are three names that currently stand out.

Amkor Technology (AMKR)

Overview: Amkor Technology is a global provider of outsourced semiconductor packaging and testing, handling everything from preparing wafers and designing packages to final system testing and shipping for chipmakers and electronics brands across the US, Europe, Japan and Asia Pacific.

Operations: Amkor generates all of its US$7.1b in revenue from semiconductor equipment and services, focused on advanced packaging and testing for a broad range of end markets.

Market Cap: US$17.3b

Amkor can be relevant for investors who want exposure to the semiconductor supply chain with a focus on packaging and test rather than wafer fabrication. Record recent revenues, momentum in advanced packaging for AI hardware and a plan to triple its AI focused portfolio in 2026 sit alongside CHIPS backed US expansion in Arizona and new capacity in Asia. Together, these factors indicate a company aiming to deepen its role with top chip customers. At the same time, reliance on a few large clients, thin margins, aggressive capex and higher funding risk from external borrowing and convertible notes highlight that the growth path involves meaningful trade-offs, which is why a closer look can be valuable.

Record revenues, AI packaging momentum and CHIPS backed expansion are only half the story. Use the analysis report for Amkor Technology to see how funding risk and customer concentration could change the equation.

Intuitive Surgical (ISRG)

Overview: Intuitive Surgical develops robotic systems like the da Vinci Surgical System and Ion endoluminal platform that help doctors perform minimally invasive surgeries and lung biopsies with more precision and smaller incisions in hospitals around the world.

Operations: Intuitive Surgical generates US$10.6b in revenue primarily from surgical and medical equipment, with around US$7.1b from the United States and US$3.5b from international markets.

Market Cap: US$162.1b

Intuitive Surgical earns most of its money not just from selling robots but from the ongoing instruments, services and digital tools that support roughly 9,500 installed da Vinci systems, and this recurring stream is now 83% of revenue. That helps explain the company’s high margins and high quality earnings, even as investors weigh a rich P/E multiple, external funding reliance and regulatory noise such as recent FDA recalls on older instruments. Recent quarters have highlighted double digit procedure growth, strong international uptake and an expanding da Vinci 5 rollout. However, the share price has lagged the broader US market and some analysts argue the stock trades well above estimated fair value. For investors, the key question is whether this recurring revenue engine justifies paying up for quality or calls for patience instead.

Intuitive Surgical’s accelerating procedure growth and 83% recurring revenue can make the rich P/E look less straightforward than it seems. See how the analyst forecasts for Intuitive Surgical stack up against that valuation risk that few are talking about.

Catalyst Pharmaceuticals (CPRX)

Overview: Catalyst Pharmaceuticals is a US based commercial biopharma company that develops and sells treatments for rare neurological and neuromuscular diseases, including LEMS, certain seizure disorders and Duchenne muscular dystrophy through branded drugs such as Firdapse, Fycompa and Agamree.

Operations: Catalyst generates about US$589m in revenue from the development and commercialization of drug products, currently all from the United States.

Market Cap: US$3.4b

Catalyst Pharmaceuticals brings together a concentrated rare disease portfolio, high margins and a solid balance sheet, with growth driven by broader diagnosis, better payer coverage and an accelerating Agamree rollout that helps reduce dependence on Firdapse. At the same time, reliance on a handful of drugs, pending patent litigation around Firdapse, a relatively thin late stage pipeline and rising SG&A tied to an expanded sales force mean the story is not risk free. In addition, the share price sits well below one fair value estimate and there is active M&A interest. Overall, this is a company where the balance between resilience and concentration risk deserves a closer look.

Accelerating rare disease revenues and a solid balance sheet can make Catalyst’s concentration risk easy to underestimate. See how the analysis report for Catalyst Pharmaceuticals ties together patent battles, M&A interest, and one underappreciated twist.

The three stocks in this article are only a starting point, and the full Low-Risk Leaders screener reveals 64 more companies with similarly compelling low risk stories and balance sheet strength. Use Simply Wall St to identify and analyze the specific catalysts, risk scores and business narratives that matter most to you, so you can focus on the highest conviction ideas within this theme.

Take Control of Your Investment Journey

If Catalyst Pharmaceuticals or any of these companies sound like a great opportunity, register for FREE with Simply Wall St and add your top picks to a Watchlist to monitor the share price against the fair value for the ideal entry point. Once you've made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates. Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives. By uncovering hidden catalysts and risks early, you'll accelerate your decision-making and stay one step ahead of the market.

Seeking Fresh Alternatives Before They Fly?

New ideas can move from quiet accumulation to full breakout before most investors even notice. Spot fresh momentum while it matters, under the radar for now, and get in early.

• Catch quality names with strong cash generation and robust fundamentals through the curated 51 high quality undervalued stocks, before potential positive sentiment spreads and ideal entry ranges start dropping.
• Ride the build out of next gen computing with a focused group of 26 quantum computing stocks that could benefit if interest in advanced processing shifts from niche to mainstream.
• Tap into powerful automation trends by scanning 32 robotics and automation stocks curated for companies building the machines, sensors and software that keep industrial and consumer systems running.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.